Отказ от ответственности

evrazkar

Евразийский Кардиологический Журнал

Eurasian heart journal

2225-16852305-0748

Евразийская ассоциация кардиологов

10.38109/2225-1685-2023-1-6-65

evrazkar-6365

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Евразийские клинические рекомендации по диагностике и лечению вторичных (симптоматических) форм артериальной гипертонии (2022)

Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)

https://orcid.org/0000-0002-9822-4357

Чазова

И. Е.

Chazova

I. E.

Чазова Ирина Евгеньевна (председатель), доктор медицинских наук, профессор, академик РАН, заместитель генерального директора по научно-экспертной работе, руководитель отдела гипертонии

Москва

Irina E. Chazova, Prof., Dr. of Sci. (Med.), Academician of RAS, Deputy General Director for Scientific and Expert Work, Head of Department of Hypertension

Moscow

https://orcid.org/0000-0002-8826-9690

Чихладзе

Н. М.

Chikhladze

N. M.

Чихладзе Новелла Михайловна (сопредседатель), доктор медицинских наук, профессор, ведущий научный сотрудник отдела гипертонии

Москва

Novella M. Chikhladze, Prof., Dr. of Sci. (Med.), Leading Researcher of Department of Hypertension

Moscow

https://orcid.org/0000-0001-5215-4894

Блинова

Н. В.

Blinova

N. V.

Блинова Наталия Владимировна (секретарь), кандидат медицинских наук, старший научный сотрудник отдела гипертонии

ул. 3-я Черепковская, д. 15а, Москва 121552

Nataliya V. Blinova, Cand. of Sci. (Med.), Senior Researcher of Department of Hypertension

3rd Cherepkovskaya street, 15a, Moscow 121552

nat-cardio1@ya.ru

https://orcid.org/0000-0002-6674-6441

Белая

Ж. Е.

Belaya

Zh. E.

Белая Жанна Евгеньевна, доктор медицинских наук, главный научный сотрудник, заведующая отделением нейроэндокринологии и остеопатии, профессор кафедры эндокринологии института высшего и дополнительного образования

Москва

Zhanna E. Belaya, Dr. of Sci. (Med.), Chief Researcher, Head of the Department of Neuroendocrinology and Osteopathy, Professor of the Department of Endocrinology, Institute of Higher and Further Education

Moscow

https://orcid.org/0000-0001-9853-9087

Данилов

Н. М.

Danilov

N. M.

Данилов Николай Михайлович, доктор медицинских наук, ведущий научный сотрудник отдела гипертонии

Москва

Nikolay M Danilov, Dr. of Sci. (Med.), Leading Researcher of Department of Hypertension

Moscow

https://orcid.org/0000-0002-3140-5030

Елфимова

Е. М.

Elfimova

E. M.

Елфимова Евгения Михайловна, кандидат медицинских наук, старший научный сотрудник лаборатории апноэ сна

Москва

Evgeniya M. Elfimova, Cand. of Sci. (Med.), Senior Researcher, Sleep Apnea Laboratory

Moscow

https://orcid.org/0000-0001-5918-9969

Литвин

А. Ю.

Litvin

A. Yu.

Литвин Александр Юрьевич, доктор медицинских наук, профессор, главный научный сотрудник, руководитель лаборатории апноэ сна

Москва

Alexander Yu. Litvin, Dr. of Sci. (Med.), Chief Researcher, Head of the Sleep Apnea Laboratory

Moscow

https://orcid.org/0000-0001-7041-0732

Рожинская

Л. Я.

Rozhinskaya

L. Ya.

Рожинская Людмила Яковлевна, доктор медицинских наук, профессор, главный научный сотрудник отделения нейроэндокринологии и остеопатии

Москва

Liudmila Ya. Rozhinskaya, Prof., Dr. of Sci. (Med.), Chief Researcher, Department of Neuroendocrinology and Bone Disease

Moscow

https://orcid.org/0000-0002-8538-5354

Свириденко

Н. Ю.

Sviridenko

N. Yu.

Свириденко Наталья Юрьевна, доктор медицинских наук, профессор, заместитель директора Института клинической эндокринологии по лечебной работе, главный научный сотрудник отдела терапевтической эндокринологии, ФГБУ «НМИЦ эндокринологии» Минздрава России; профессор института высшего и дополнительного профессионального образования

Москва

Natalya Yu. Sviridenko, Dr. of Sci. (Med.), Professor, Deputy Director for Therapeutic Work of Institute of Clinical Endocrinology, Senior Researcher, Department of Therapeutic Endocrinology, The National Medical Research Centre for Endocrinology; Professor, The Institute of Higher and Additional Professional Education

Moscow

https://orcid.org/0000-0002-7747-4461

Швецов

М. Ю.

Shvetsov

M. Yu.

Швецов Михаил Юрьевич, кандидат медицинских наук, доцент кафедры внутренних, профессиональных болезней и ревматологии

Москва

Mikhail Yu. Shvetsov, Cand. of Sci. (Med.), Associate Professor, Department of Internal, Occupational Diseases, and Rheumatology

Moscow

https://orcid.org/0000-0001-5655-3913

Азизов

В. А.

Azizov

V. A.

Азизов Васадат Алиевич, доктор медицинских наук, профессор, заведующий кафедрой внутренних болезней

Баку

Vasadat A. Azizov, Dr. of Sci. (Med.), Professor, Head of the Department of Internal Diseases

Baku

https://orcid.org/0000-0002-8120-6267

Григоренко

Е. А.

Grigorenko

E. A.

Григоренко Елена Александровна, кандидат медицинских наук, доцент, профессор кафедры кардиологии и внутренних болезней

Минск

Elena A. Grigorenko, Prof., Dr. of Sci. (Med.), Associate Professor, Professor of the Department of Cardiology and Internal Medicine

Minsk

https://orcid.org/0000-0002-9088-721X

Митьковская

Н. П.

Mit’kovskaja

N. P.

Митьковская Наталья Павловна, доктор медицинских наук, профессор, директор, Республиканский научно-практический центр «Кардиология»; заведующая кафедрой кардиологии и внутренних болезней, Белорусский государственный медицинский университет

Минск

Nataliya P. Mit’kovskaja, Dr. of Sci. (Med.), Professor, director, Republican Scientific and Practical Center «Cardiology»; Head of the Department of Cardiology and Internal Medicine, Belarusian State Medical University

Minsk

Мустафаев

И. И.

Mustafaev

I. I.

Мустафаев Исах Исмаилович, доктор медицинских наук, профессор кафедры терапии

Баку

Isakh I. Mustafaev, Dr. of Sci. (Med.), Professor

Baku

Полупанов

А. Г.

Polupanov

A. G.

Полупанов Андрей Геннадьевич, доктор медицинских наук, профессор, старший научный сотрудник

Бишкек

Andrey G. Polupanov, Dr. of Sci. (Med.), Professor, Senior Researcher

Bishkek

https://orcid.org/0000-0003-2172-9776

Сарыбаев

А. Ш.

Sarybaev

A. Sh.

Сарыбаев Акпай Шогаибович, доктор медицинских наук, профессор, директор

Бишкек

Akpaj Sh. Sarybaev, Dr. of Sci. (Med.), Professor, Director

Bishkek

Хамидуллаева

Г. А.

Hamidullaeva

G. A.

Хамидуллаева Гульноз Абдусаттаровна, доктор медицинских наук профессор, руководитель отделения Артериальные Гипертензии

Ташкент

Gul’noz A. Hamidullaeva, Dr. of Sci. (Med.), Professor, Head of the Department of Arterial Hypertension

Tashkent

НИИ клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова» Минздрава РоссииРоссияA.L. Myasnikov Research Institute of Cardiology, E.I. Chazov National Medical Research Center Of CardiologyRussian Federation

НИИ клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова» Минздрава РоссииРоссияA.L. Myasnikov Institute of Clinical Cardiology, E.I. Chazov National Medical Research Center Of CardiologyRussian Federation

ФГБУ «Национальный Медицинский Исследовательский Центр Эндокринологии» Минздрава РоссииРоссияThe National Medical Research Center for EndocrinologyRussian Federation

НИИ клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии» Минздрава России, Москва, Российская ФедерацияРоссияA.L. Myasnikov Institute of Clinical Cardiology, E.I. Chazov National Medical Research Center Of CardiologyRussian Federation

ФГБУ «Национальный Медицинский Исследовательский Центр Эндокринологии» Минздрава РоссииРоссияThe National Medical Research Centre for EndocrinologyRussian Federation

Институт клинической эндокринологии по лечебной работе; ФГБУ «Национальный Медицинский Исследовательский Центр Эндокринологии» Минздрава России; Института высшего и дополнительного профессионального образованияРоссияInstitute of Clinical Endocrinology; The National Medical Research Centre for Endocrinology; The Institute of Higher and Additional Professional EducationRussian Federation

Институт клинической медицины им. Н.В. Склифосовского, ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation

1-го Азербайджанский Медицинский УниверситетАзербайджан1st Azerbaijan Medical UniversityAzerbaijan

Белорусский государственный медицинский университетБеларусьBelarusian State Medical UniversityBelarus

Белорусский государственный медицинский университетБеларусьRepublican Scientific and Practical Center «Cardiology»; Belarusian State Medical UniversityBelarus

Азербайджанский институт усовершенствования врачей им. А. АлиеваАзербайджанAzerbaijan State Advanced Training Institute for Doctors named by A.AliyevAzerbaijan

Национальный центр кардиологии и терапии им. академика М.М. Миррахимова при Минздраве Киргизской РеспубликиКыргызстанMM. Mirrakhimov National Center for Cardiology and TherapyKyrgyzstan

Республиканский специализированный научно-практический медицинский центр кардиологииУзбекистанRepublican Specialized Scientific and Practical Medical Center for CardiologyUzbekistan

2023

01032023

01665

Copyright © Чазова И.Е., Чихладзе Н.М., Блинова Н.В., Белая Ж.Е., Данилов Н.М., Елфимова Е.М., Литвин А.Ю., Рожинская Л.Я., Свириденко Н.Ю., Швецов М.Ю., Азизов В.А., Григоренко Е.А., Митьковская Н.П., Мустафаев И.И., Полупанов А.Г., Сарыбаев А.Ш., Хамидуллаева Г.А., 2023

2023

Чазова И.Е., Чихладзе Н.М., Блинова Н.В., Белая Ж.Е., Данилов Н.М., Елфимова Е.М., Литвин А.Ю., Рожинская Л.Я., Свириденко Н.Ю., Швецов М.Ю., Азизов В.А., Григоренко Е.А., Митьковская Н.П., Мустафаев И.И., Полупанов А.Г., Сарыбаев А.Ш., Хамидуллаева Г.А.

Chazova I.E., Chikhladze N.M., Blinova N.V., Belaya Z.E., Danilov N.M., Elfimova E.M., Litvin A.Y., Rozhinskaya L.Y., Sviridenko N.Y., Shvetsov M.Y., Azizov V.A., Grigorenko E.A., Mit’kovskaja N.P., Mustafaev I.I., Polupanov A.G., Sarybaev A.S., Hamidullaeva G.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.heartj.asia/jour/article/view/6365

Отказ от ответственности

Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

рекомендацииартериальная гипертониявторичные гипертониирезистентная гипертонияэндокринные гипертониипаренхиматозные заболевания почекреноваскулярная гипертониясиндром обструктивного апноэ сналекарственная гипертония

guidelinesarterial hypertensionsecondary hypertensionresistant hypertensionendocrine hypertensionrenal parenchymal diseaserenovascular hypertensionobstructive sleep apnea syndromedrug-induced hypertension

References1

Egan B.M., Kjeldsen S.E., Grassi G. et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148- 1153. doi: 10.1097/HJH.0000000000002021

Viera A.J., Neutze D.M. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician. 2010;82(12):1471-1478

Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J Hypertens. 2019 Jan;37(1):226]. J Hypertens. 2018;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940

Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6–31. doi: 10.26442/2075082X.2019.1.190179

Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31 (in Russ). doi: 10.26442/2075082X.2019.1.190179

Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510–526. doi: 10.1161/CIRCULATIONAHA.108.189141

Carey R.M., Calhoun D.A., Bakris G.L. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084

Аксенова А.В., Сивакова О.А., Блинова Н.В. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив. 2021;93(9):1018–1029. doi: 10.26442/00403660.2021.09.201007.

Aksenova A.V., Sivakova O.A., Blinova N.V. et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii arkhiv. 2021;93(9):1018–1029. doi: 10.26442/00403660.2021.09.201007

Rimoldi S.F., Scherrer U., Messerli F.H. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014 May 14;35(19):1245- 54. doi: 10.1093/eurheartj/eht534

Арабидзе Г.Г. Симптоматические артериальные гипертонии. В кн.: Болезни сердца и сосудов. Под ред. Е.И. Чазова. – М.: Медицина, 1992;3:196-226.

Arabidze G.G. Symptomatic arterial hypertension. In: Diseases of the heart and blood vessels. Ed. E.I. Chazov. - M.: Medicine, 1992;3:196-226. (in Russ).

Cingolani O.H. Cardiovascular risks and organ damage in secondary hypertension. Endocrinol Metab Clin North Am. 2019 Dec;48(4):657- 666. doi: 10.1016/j.ecl.2019.08.015

Ратнер Н.А. Артериальные гипертонии. М.: Медицина,1974. – 415 с.

Ratner N.A. Arterial hypertension. M.: Medicine, 1974. – 415p. (in Russ).

Чихладзе Н.М. Симптоматические (вторичные) артериальные гипертонии: диагностика и лечение. М.: Медицинское информационное агентство, 2018. — 168 с. ISBN 978-5-907098-01-5

12 Chikhladze N.M. Symptomatic (secondary) arterial hypertension: diagnosis and treatment. Moscow: Medical Information Agency, 2018. — 168. (in Russ.). ISBN 978-5-907098-01-5

Young W.F. Jr., Calhoun D.A., Lenders J.W.M. et al. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement, Endocrine Reviews, 2017;38(2):103–122. doi: 10.1210/er.2017-00054

Rossi G.P., Bisogni V., Rossitto G. et al. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Press Cardiovasc Prev. 2020;27(6):547-560. doi: 10.1007/s40292-020-00415-9

Pedrosa R.P., Drager L.F., Gonzaga C.C. et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011 Nov;58(5):811-7. doi: 10.1161/HYPERTENSIONAHA.111.179788

Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012 Jan;125(1):14-22. doi: 10.1016/j.amjmed.2011.05.024

Ettehad D., Emdin C.A., Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016 Apr;34(4):613-22. doi: 10.1097/HJH.0000000000000881

Sundström J., Arima H., Jackson R. et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015 Feb 3;162(3):184-91. doi: 10.7326/M14-0773

Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009 May;27(5):923-34. doi: 10.1097/HJH.0b013e32832aa6b5

Arguedas J.A., Leiva V., Wright J.M. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3

Unger T., Borghi C., Charchar F. et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982-1004. doi: 10.1097/HJH.0000000000002453

Chen T., Shao F., Chen K. et al. Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension: A Secondary Analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 Jun 1;182(6):660-667. doi: 10.1001/jamainternmed.2022.1657. Erratum in: JAMA Intern Med. 2022 Jul 5;:null.

Odden M.C., McClure L.A., Sawaya B.P. et al. Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension. 2016 Jan;67(1):63-9. doi: 10.1161/HYPERTENSIONAHA.115.06480. Epub 2015 Nov 9. PMID: 26553236

Qaseem A., Wilt T.J., Rich R. et al. Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430- 437. doi: 10.7326/M16-1785. Epub 2017 Jan 17. Erratum in: Ann Intern Med. 2018 Apr 3;168(7):530-532.

Garrison S.R., Kolber M.R., Korownyk C.S. et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017 Aug 8;8(8):CD011575. doi: 10.1002/14651858.CD011575.pub2

Чазова И.Е., Шестакова М.В., Жернакова Ю.В. Российское медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020;17(1):7–45. doi: 10.26442/2075082X.2020.1.200051

Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020;17(1):7–45. (in Russ). doi: 10.26442/2075082X.2020.1.200051

Brunström M., Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28-36. doi: 10.1001/jamainternmed.2017.6015

MacDonald T.M., Williams B., Webb D.J. et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am Heart Assoc. 2017 Nov 18;6(11):e006986. doi: 10.1161/JAHA.117.006986

Williams B., MacDonald T.M., Morant S.V. et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8

Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038

Dahlöf B., Sever P.S., Poulter N.R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895- 906. doi: 10.1016/S0140-6736(05)67185-1

Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension. 2010 Feb;55(2):399-407. doi: 10.1161/HYPERTENSIONAHA.109.139816

Volpe M., Christian Rump L., Ammentorp B., Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/ hydrochlorothiazide combination. Clin Drug Investig. 2012 Oct 1;32(10):649-64. doi: 10.1007/BF03261919

Liu L., Xu B., Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257-263. doi: 10.1080/10641963.2016.

ONTARGET Investigators, Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine. 2008 Apr;358(15):1547-1559. doi: 10.1056/nejmoa0801317

Catapano A.L., Graham I., De Backer G. et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272

Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3(28):5–22.

Ezhov M.V., Sergienko I.V., Aronov D.M. et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Atherosclerosis and dyslipidemia. 2017;3(28):5–22. (in Russ).

Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0

van den Born B.H., Lip G.Y.H., Brguljan-Hitij J. et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37- 46. doi: 10.1093/ehjcvp/pvy032

Vaughan C.J., Delanty N. Hypertensive emergencies. Lancet. 2000 Jul 29;356(9227):411-7. doi: 10.1016/S0140-6736(00)02539-3

Кутырина И.М., Швецов М.Ю., Фомин В.В. и соавт. Клинические рекомендации. Диагностика и лечение артериальной гипертензии при хронической болезни почек. Клиническая нефрология. 2015;(4):4- 29.

Kutyrina I.M., Shvetsov M.YU., Fomin V.V. et al. Clinical guidelines. Diagnosis and treatment of arterial hypertension in chronic kidney disease. Klinicheskaya nefrologiya. 2015;(4):4-29 (In Russ.).

Ridao N., Luño J., García de Vinuesa S. et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant. 2001;16 Suppl 1:70-73. http://www.ncbi.nlm.nih.gov/pubmed/18457801

Boesen E.I., Kakalij R.M. Autoimmune-Mediated Renal Disease and Hypertension. Vol 135.; 2021:2165-2196. doi: 10.1042/CS20200955

Кутырина И.M., Мартынов С.A., Швецов М.Ю. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Терапевтический архив. 2004;(9):10- 15.

Kutyrina I.M., Martynov S.A., Shvetsov M.YU. Arterial hypertension in chronic glomerulonephritis: detection rate and treatment efficacy. Terapevticheskii arkhiv. 2004;(9):10-15 (In Russ.).

Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;Suppl (3 (1)):1- 150. doi: 10.1038/ki.2013.243

Моисеев В.С., Мухин Н.А., ред. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая нефрология. 2014;(2):4-29.

Moiseev V.S., Mukhin N.A., ed. National guideline. Cardiovascular risk and chronic kidney disease: strategies for cardionephroprotection.. Klinicheskaya nefrologiya. 2014;(2):4-29 (In Russ.).

Шилов Е.М., Смирнов А.В., Козловская Н.Л., ред. Нефрология. Клинические Рекомендации. ГЭОТАР-Медиа; 2016.

Shilov E.M., Smirnov A.V., Kozlovskaya N.L., ed. Nephrology. Clinical guidelines. GEHOTAR-Media; 2016 (In Russ.).

Weiner D.E., Tighiouart H., Elsayed E.F. et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50(3):217- 224. doi: 10.1016/j.jacc.2007.03.037

Мартынов С.А., Швецов М.Ю., Кутырина И.М. Нарушения суточного ритма артериального давления у больных хроническим гломерулонефритом. Терапевтический архив. 2006;(1):23-27.

Martynov S.A., Shvetsov M.YU., Kutyrina I.M. Blood pressure circadian rhythm disorders in patients with chronic glomerulonephritis. Terapevticheskii arkhiv. 2006;(1):23-27 (In Russ.).

Rahman M., Wang X., Bundy J.D. et al. Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2020;31(11):2609- 2621. doi: 10.1681/ASN.2020030236

Chen T.K., Knicely D.H., Grams M.E. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294-1304. doi: 10.1001/JAMA.2019.14745

Sarafidis P.A., Persu A., Agarwal R. et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney. Nephrol Dial Transplant. 2017;32(4):620-640. doi: 10.1093/NDT/GFW433

Lv J., Ehteshami P., Sarnak M.J. et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185(11):949-957. doi: 10.1503/cmaj.121468

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012;2(5):337-414.

SPRINT Research Group, Wright J.T., Williamson J.D., et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. doi: 10.1056/NEJMoa1511939

Whelton P.K., Carey R.M., Aronow W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical pr. Hypertension. 2018;71(6):E13-E115. doi: 10.1161/HYP.0000000000000065/-/DC2

Cheung A.K., Chang T.I., Cushman W.C. et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi: 10.1016/J.KINT.2020.11.003

National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(1-290)

Jafar T.H., Stark P.C., Schmid C.H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252. http://www.ncbi.nlm.nih.gov/pubmed/12965979

Cobb M., Pacitti D. The Importance of Sodium Restrictions in Chronic Kidney Disease. J Ren Nutr. 2018;28(5):e37-e40. doi: 10.1053/j.jrn.2018.02.001

Cibulka R., Racek J. Metabolic disorders in patients with chronic kidney failure. Physiol Res. 2007;56(6):697-705. doi: 10.33549/PHSIOLRES.931128

Lee S., Kang S., Joo Y.S. et al. Smoking, Smoking Cessation, and Progression of Chronic Kidney Disease: Results From KNOW-CKD Study. Nicotine Tob Res. 2021;23(1):92-98. doi: 10.1093/NTR/NTAA071

Li Y., Zhu B., Song N. et al. Alcohol consumption and its association with chronic kidney disease: Evidence from a 12-year China health and Nutrition Survey. Nutr Metab Cardiovasc Dis. 2022;32(6):1392-1401. doi: 10.1016/J.NUMECD.2022.02.012

Lotan Y., Daudon M., Bruyère F. et al. Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr Opin Nephrol Hypertens. 2013;22 Suppl 1(Suppl 1):S1-10. doi: 10.1097/MNH.0b013e328360a268

Sontrop J.M., Dixon S.N., Garg A.X. et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a crosssectional analysis of NHANES data. Am J Nephrol. 2013;37(5):434-442. doi: 10.1159/000350377

Wagner S., Merkling T., Metzger M., et al. Water intake and progression of chronic kidney disease: the CKD-REIN cohort study. Nephrol Dial Transplant. 2022;37(4):730-739. doi: 10.1093/NDT/GFAB036

Ikizler T.A., Burrowes J.D., Byham-Gray L.D., et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3):S1-S107. doi: 10.1053/J.AJKD.2020.05.006

Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998;352:1252-1256.

Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. doi: 10.1056/NEJMOA011161

Vogt L., Waanders F., Boomsma F. et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):999-1007. doi: 10.1681/ASN.2007060693

Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173- 1181. doi: 10.1016/S0140-6736(09)62100-0

Ohno S., Ishii A., Yanagita M. et al. Calcium channel blocker in patients with chronic kidney disease. Clin Exp Nephrol. 2022;26(3):207-215. doi: 10.1007/S10157-021-02153-1

Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903. doi: 10.1056/NEJMoa1303154

Maione A., Navaneethan S.D., Graziano G., et al. Angiotensinconverting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-2847. doi: 10.1093/ndt/gfq792

Dickinson H.O., Mason J.M., Nicolson D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233. doi: 10.1097/01.hjh.0000199800.72563.26

Покровский А.В., Богатов Ю.П. Вазоренальная гипертония. Гл. в кн.: Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: МедиаМедика, 2005; 95-117.

Pokrovskij А.V., Bogatov YU.P. Vasorenal hypertension. Ch. in the book: Arterial hypertension guidance. Ed. E.I. Chazova, I.E. Chazovoi. Moscow: MediaMedica, 2005; 95-117 (in Russ.).

Шилов Е.М., Батюшкин М.М. Реноваскулярная артериальная гипертензия и ишемическая болезнь почек. В кн.: Нефрология. Клинические рекомендации. Под ред. Е.М.Шилова, А.В.Смирнова, Н.Л. Козловской. M.: ГЭОТАР-Медиа, 2016; 449-460.

Shilov E.M., Batyushkin M.M. Renovascular hypertension and ischemic kidney disease. In: Nephrology. Clinical guidelines. Ed. E.M. Shilova, A.V. Smirnova, N.L. Kozlovskaya. M.: GEOTAR-Media, 2016; 449-460 (in Russ).

Мухин Н.А., Фомин В.В. Атеросклеротический стеноз почечных артерий. В кн.: Руководство по атеросклерозу и ишемической болезни сердца. Под ред. Е.И Чазова, В.В. Кухарчука, С.А. Бойцова. Media Medica, 2007; 248-273.

Mukhin N.А., Fomin V.V. Atherosclerotic stenosis of the renal arteries. In: Guide to atherosclerosis and coronary heart disease. Ed. E.I. Chazov, V.V. Kukharchuk, S.A. Boytsov. Media Medica, 2007; 248-273 (in Russ).

Herrmann S.M., Textor S.C. Renovascular Hypertension. Endocrinol Metab Clin North Am. 2019 Dec;48(4):765-778. doi: 10.1016/j.ecl.2019.08.007

de Mast Q., Beutler J.J. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009 Jul;27(7):1333-40. doi: 10.1097/HJH.0b013e328329bbf4

Boutari C., Georgianou E., Sachinidis A. et al. Renovascular Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):24-29. doi: 10.2174/1573402115666190416153321

Mousa A.Y., Campbell J.E., Stone P.A. et al. Short- and long-term outcomes of percutaneous transluminal angioplasty/stenting of renal fibromuscular dysplasia over a ten-year period. J Vasc Surg. 2012 Feb;55(2):421-7. doi: 10.1016/j.jvs.2011.09.006

Tafur-Soto J.D., White C.J. Renal artery stenosis. Cardiology Clinics 2015; 33(1):59–73. doi: 10.1016/j.ccl.2014.09.006

Фомин В.В., Кутырина И.М., Швецов М.Ю. Ишемическая болезнь почек. В кн.: Нефрология. Национальное руководство. Краткое издание. Гл. ред. Н.А Мухин. – М.: «ГЭОТAР-Медиа», 2014. – C. 377-386.

Fomin V.V., Kutyrina I.M., Shvetsov M.Yu. Ischemic kidney disease. In the book: Nephrology. National leadership. Сoncise edition. Ch. ed. N.A Mukhin. - M.: «GEOTAR-Media», 2014. - C. 377-386 (in Russ).

Jennings C.G., Houston J.G., Severn A. et al. Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep. 2014 Jun;16(6):416. doi: 10.1007/s11883-014-0416-2.

Aboyans V., Ricco J.B., Bartelink M.E.L. et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763- 816. doi: 10.1093/eurheartj/ehx095

AbuRahma A.F., Yacoub M. Renal imaging: duplex ultrasound, computed tomography angiography, magnetic resonance angiography, and angiography. Semin Vasc Surg. 2013 Dec;26(4):134-43. doi: 10.1053/j.semvascsurg.2014.06.001

Chi Y.W., White C.J., Thornton S. et al. Ultrasound velocity criteria for renal in-stent restenosis. J Vasc Surg. 2009 Jul;50(1):119-23. doi: 10.1016/j.jvs.2008.12.066

Schäberle W., Leyerer L., Schierling W. et al. Ultrasound diagnostics of renal artery stenosis. Gefässchirurgie. 2016; 1(21):4–13. doi: 10.1007/s00772-015-0060-3

Fananapazir G., McGahan J.P., Corwin M.T. et al. Screening for Transplant Renal Artery Stenosis: Ultrasound-Based Stenosis Probability Stratification. AJR Am J Roentgenol. 2017 Nov;209(5):1064-1073. doi: 10.2214/AJR.17.17913

Tan K.T., van Beek E.J., Brown P.W. et al. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol. 2002 Jul;57(7):617-24. doi: 10.1053/crad.2002.0941

Bley T., Francois C., Schiebler M. Non-contrast-enhanced MRA of renal artery stenosis: validation against DSA in a porcine model. European Radiology 2016;26(2):547–55. doi: 10.1007/s00330-015-3833-x

Weber-Mzell D. Coronary anatomy predicts presence or absence of renal artery stenosis. A prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. European Heart Journal, 2002;23(21):1684–1691. doi: 10.1053/euhj.2002.3314

Kim D., Porter D. H., Brown R. et al. Renal Artery Imaging: A Prospective Comparison of Intra-Arterial Digital Subtraction Angiography with Conventional Angiography. Angiology.1991;42(5):345–357. doi: 10.1177/000331979104200501

Safian R.D. Renal artery stenosis. Prog Cardiovasc Dis. 2021 MarApr;65:60-70. doi: 10.1016/j.pcad.2021.03.003

Klein A.J., Jaff M.R., Gray B.H. et al. SCAI appropriate use criteria for peripheral arterial interventions: An update. Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E90-E110. doi: 10.1002/ccd.27141

Balafa O., Kalaitzidis R., Siamopoulos K.C. Optimal medical management in patients with renovascular hypertension. Am J Cardiovasc Drugs. 2013 Apr;13(2):71-8. doi: 10.1007/s40256-013-0011-x

Hackam D.G., Spence J.D., Garg A.X. et al. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007 Dec;50(6):998-1003. doi: 10.1161/HYPERTENSIONAHA.107.097345

100

Manaktala R., Tafur-Soto J.D., White C.J. Renal Artery Stenosis in the Patient with Hypertension: Prevalence, Impact and Management. Integr Blood Press Control. 2020 Jun 2;13:71-82. doi: 10.2147/IBPC.S248579.

101

Evans K.L., Tuttle K.R., Folt D.A. et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol. 2014 Jul;9(7):1199-206. doi: 10.2215/CJN.11611113

102

Chrysochou C., Foley R.N., Young J.F. et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant. 2012 Apr;27(4):1403-9. doi: 10.1093/ndt/gfr496

103

Chen Y., Pan H., Luo G. et al. Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis. J Int Med Res. 2021 Jan;49(1):300060520983585. doi: 10.1177/0300060520983585

104

Parikh S.A., Shishehbor M.H., Gray B.H. et al. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1163-71. doi: 10.1002/ccd.25559

105

Mangiacapra F., Trana C., Sarno G. et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv. 2010 Dec;3(6):537-42. doi: 10.1161/CIRCINTERVENTIONS.110.957704

106

Zeller T., Müller C., Frank U. et al. Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis. Catheter Cardiovasc Interv. 2003 Apr;58(4):510-5. doi: 10.1002/ccd.10435

107

Mitchell J.A., Subramanian R., White C.J. et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: renal fractional flow reserve. Catheter Cardiovasc Interv. 2007 Apr 1;69(5):685-9. doi: 10.1002/ccd.21095

108

Trinquart L., Mounier-Vehier C., Sapoval M. et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010 Sep;56(3):525-32. doi: 10.1161/HYPERTENSIONAHA.110.152918. Epub 2010 Jul 12.

109

Steuer J., Bergqvist D., Björck M. Surgical Renovascular Reconstruction for Renal Artery Stenosis and Aneurysm: Long-Term Durability and Survival. European Journal of Vascular and Endovascular Surgery. 2018; 57(4):562-568. doi: 10.1016/j.ejvs.2018.09.014

110

Зотиков А.Е., Белоярцев Д.Ф. Хирургия поражений почечных артерий. Гл. в кн. Хирургия почечных сосудов. Под ред. Ревишвили А.Ш., Покровского А.В., Зотикова А.Е. М.: Фонд «Русские Витязи», 2021; 36-48.

Zotikov A.E., Beloyartsev D.F. Surgery for lesions of the renal arteries. Ch. in book. Surgery of the renal vessels. Ed. Revishvili A.Sh., Pokrovsky A.V., Zotikova A.E. Moscow: Russian Knights Foundation, 2021; 36-48 (in Russ).

111

Conlon P.J., Little M.A., Pieper K. et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001 Oct;60(4):1490-7. doi: 10.1046/j.1523-1755.2001.00953.x

112

Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18. doi: 10.1111/j.1365-2265.2007.02775.x

113

Funder J.W., Carey R.M., Mantero F. et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061

114

Rossi G.P., Bisogni V., Bacca A.V. et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens. 2020;5. doi: 10.1016/j.ijchy.2020.100029

115

Mulatero P., Stowasser M., Loh K.C. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-50. doi: 10.1210/jc.2003-031337

116

Meng Z., Zhou L., Dai Z. et al. The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal. Front Med (Lausanne). 2020;7:136. doi: 10.3389/fmed.2020.00136

117

Young W.F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: 10.1111/joim.12831

118

Mulatero P., Monticone S., Deinum J. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020 Oct;38(10):1919- 1928. doi: 10.1097/HJH.0000000000002510.

119

Mosso L., Carvajal C., González A. et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-5. doi: 10.1161/01.HYP.0000079505.25750.11

120

Douma S., Petidis K., Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008 Jun 7;371(9628):1921-6. doi: 10.1016/S0140-6736(08)60834-X. Erratum in: Lancet. 2008 Dec 13;372(9655):2022.

121

Schmiemann G., Gebhardt K., Hummers-Pradier E. et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med. 2012;25:98-103. doi: 10.3122/jabfm.2012.01.110099

122

Чихладзе Н.М. Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии. Системные гипертензии. 2020; 17 (4): 20–23. doi: 10.26442/2075082X.2020.4.200338

Chikhladze N.M. Primary hyperaldosteronism as a possible cause of resistant arterial hypertension. Systemic Hypertension. 2020; 17 (4): 20–23. (In Russ.) doi: 10.26442/2075082X.2020.4.200338

123

Rossi G.P., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. doi:10.1016/j.jacc.2006.07.059

124

Woo K., Waisman J., Melamed J. et al. Primary aldosteronism caused by unilateral adrenal hyperplasia. Rev Urol. 2000 Spring;2(2):100-4.

125

Goh B.K., Tan Y.H., Chang K.T. et al. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg. 2007;31(1):72-79. doi: 10.1007/s00268-005-0594-8

126

Zennaro M.C., Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016;77(3):214-9. doi: 10.1016/ando.2016.02.00

127

Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. – М.: Медицина, 1984. 136 с.

Shkhvatsabaia IK, Chihladze NM. Giperal’dosteronizm i arterial’naia gipertoniia. Moscow: Meditsina, 1984 (in Russian).

128

Baguet J.P., Steichen O., Mounier-Véhier C. et al. SFE/SFHTA/ AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016;77(3):187-91. doi: 10.1016/j.ando.2016.01.006

129

Amar L., Plouin P.F., Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9. doi: 10.1186/1750-1172-5-9

130

Чихладзе Н.М. Характер течения артериальной гипертонии при низкорениновом гиперальдостеронизме. Системные гипертензии. 2019;16(4):22–26. doi: 10.26442/2075082X.2019.4.190574

Chikhladze N.M. The nature of the course of arterial hypertension in low-renin hyperaldosteronism. Systemic Hypertension. 2019; 16 (4): 22–26 (In Russ). doi: 10.26442/2075082X.2019.4.190574

131

Brown J.M., Robinson-Cohen C., Luque-Fernandez M.A. et al. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann Intern Med. 2017;167(9):630-641. doi: 10.7326/M17-0882

132

Monticone S., D’Ascenzo F., Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4

133

Pan C.T., Tsai C.H., Chen Z.W. et al. Atrial Fibrillation in Primary Aldosteronism. Horm Metab Res. 2020;52(6):357-365. doi: 10.1055/a1141-5989

134

Чихладзе Н.М. Первичный гиперальдостеронизм: показания для скрининга. Терапевтический архив. 2022;94(1):107–113. doi: 10.26442/00403660.2022.01.201324

Chikhladze N.M. Primary hyperaldosteronism: indications for screening. Terapevticheskii Arkhiv. 2022;94(1):107–113 (In Russ). doi: 10.26442/00403660.2022.01.201324

135

Monticone S., Burrello J., Tizzani D. et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-20. doi: 10.1016/j.jacc.2017.01.052

136

Ganguly A., Dowdy A.J., Luetscher J.A. et al. Anomalous postural response of plasma aldosterone concentration in patients with aldosteroneproducing adrenal adenoma. J Clin Endocrinol Metab. 1973. Vol. 36. N 2.P. 401-4.

137

Teresa Fuss C., Brohm K., Fassnacht M. et al. Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2022 Jan 18;107(2):e865-e873. doi: 10.1210/clinem/dgab611

138

Mulatero P., Sechi L.A., Williams T.A. et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(10):1929-1936. doi: 10.1097/HJH.0000000000002520

139

Williams T.A., Lenders J.W.M., Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3

140

Karagiannis A., Tziomalos K., Kakafika A.I. et al. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer. 2008;15(3):693-700. doi: 10.1677/ERC-08-0094

141

Sechi L.A., Colussi G.L., Novello M. et al. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery? Horm Metab Res. 2015;47(13):1000-1006. doi: 10.1055/s0035-1565128

142

Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018;90(9):115-22. doi: 10.26442/terarkh2018909115-122

Chikladze N.M., Favorova O.O., Chazova I.E. Family hyperaldosteronism type I: a clinical case and review of literature. Terapevticheskii Arkhiv. 2018;90(9):115-22 (in Russ). doi: 10.26442/terarkh2018909115-122

143

Мельниченко Г.А., Дедов И.И., Белая Ж.Е. и соавт. Болезнь Иценко-Кушинга: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы Эндокринологии. 2015; 61(2): 55–77. doi: 10.14341/proderalbl201561255-77

Melnichenko G.A., Dedov I.I., Belaya J.E. еt аl. Russian federal clinical guidelines for Cushing’s disease. clinic, diagnostics, differential diagnostics, methods of treatment Problems of endocrinology 2015; 61(2):55-77 (In Russ). doi: 10.14341/proderalbl201561255-77

144

Nieman L.K., Biller B.M.K., Findling J.W. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93(5):1526-1540. doi: 10.1210/jc.2008-0125.

145

Feelders R., Sharma S., Nieman L. Cushing’s syndrome: epidemiology and developments in disease management. CLEP 2015: 281. doi: 10.2147/CLEP.S44336

146

Марова Е.И., Белая Ж.Е., Малыгина А.А. и соавт. Болезнь Иценко-Кушинга (учебное пособие). - М.: ФГБУ “НМИЦ эндокринологии” Минздрава России, 2021. - 40 с.

Marova E.I., Belaya J.E. Malyigina A.A. et al. Itsenko-Cushing’s disease (textbook). - M.: FGBU «NMITs Endocrinology» of the Ministry of Health of Russia (In Russ).

147

Lindholm J., Juul S., Jørgensen J.O.L. et al. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study 1. The Journal of Clinical Endocrinology & Metabolism 2001;86(1):117–123. doi: 10.1210/jcem.86.1.7093

148

Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 1994;40(4):479–484. doi: 10.1111/j.1365-2265.1994.tb02486.x

149

Broder M.S., Neary M.P., Chang E. et al. Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients < 65 years old in the United States. Pituitary 2015;18(3):283–289. doi: 10.1007/s11102-014-0569-6

150

Trifanescu R., Carsote M., Caragheorgheopol A. et al. Screening for secondary endocrine hypertension in young patients. Maedica (Bucur). 2013;8(2):108–115.

151

Omura M., Saito J., Yamaguchi K. et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202. doi: 10.1291/hypres.27.193

152

Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В. и соавт. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга. Ожирение и Метаболизм. – 2013(1). – 29–34.

Belaya J.E., Rozhinskaya L.Y., Dragunova N.V. et al. Metabolic complications of endogenous hypercortisolism. Selection of patients for screening. Obesity and Metabolism. – 2013(1). – 29–34 (in Russ.).

153

Valassi E., Santos A., Yaneva M. et al. ERCUSYN Study Group. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011 Sep;165(3):383-92. doi: 10.1530/EJE-11-0272

154

Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное Руководство. 2-е изд. — М.: ГЭОТАР-Медиа; 2018.

Dedov I.I., Mellnichenko G.A. Endocrinology. National Guide. 2nd ed. — M.: GEOTAR-Media; 2018 (In Russ).

155

Белая Ж.Е., Малыгина А.А., Гребенникова Т.А. и соавт. Диагностические возможности исследования кортизола слюны в ходе малой пробы с дексаметазоном. Ожирение и метаболизм. 2020;17(1):13- 21. doi: 10.14341/omet10117

Belaya J.E., Malyigina A.A., Grebennikova T.A., Iljin A.V. et al. Diagnostic possibilities salivary cortisol during a night test with 1 mg dexamethasone. Obesity and metabolism. 2020;17(1):13-21 (In Russ). doi: 10.14341/omet10117

156

Белая Ж.Е., Ильин А.В., Мельниченко Г.А. и соавт. Автоматизированный электрохемилюминесцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. Ожирение и метаболизм. 2011;27(2):56-63.

Belaya J.E., Iljin A.V. Melnichenko G.A. et al. Automatic electrochemiluminescent method for the determination of cortisol in saliva for the diagnosis of endogenous hypercortisolism among obese patients.Obesity and metabolism. 2011;27(2):56-63 (In Russ).

157

Sereg M., Tőke J., Patócs A. et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. Steroids 2011;76(1–2):38–42. doi: 10.1016/j.steroids.2010.08.007

158

Hong A.R., Kim J.H., Hong E.S. et al Limited Diagnostic Utility of Plasma Adrenocorticotropic Hormone for Differentiation between Adrenal Cushing Syndrome and Cushing Disease. Endocrinol Metab 2015;30(3):297. doi: 10.3803/EnM.2015.30.3.297

159

Liu Z., Zhang X., Wang Z. et al. High positive predictive value of the combined pituitary dynamic enhanced MRI and high-dose dexamethasone suppression tests in the diagnosis of Cushing’s disease bypassing bilateral inferior petrosal sinus sampling. Sci Rep 2020;10(1):14694. doi: 10.1038/s41598-020-71628-0

160

Pinelli S., Barbot M., Scaroni C. et al. Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism. Ann Lab Med 2021;41(6):521–531. doi: 10.3343/alm.2021.41.6.521

161

Colao A., Petersenn S., Newell-Price J. et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med.2012;366(10):914–924. doi: 10.1056/NEJMoa1105743

162

Barbot M., Ceccato F., Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing’s Syndrome. Front Endocrinol (Lausanne). 2019 May 21;10:321. doi: 10.3389/fendo.2019.00321

163

Isidori A.M., Graziadio C., Paragliola R.M. et al, ABC Study Group. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015 Jan;33(1):44-60. doi: 10.1097/HJH.0000000000000415

164

Cicala M.V., Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92 Suppl 1:44-9. doi: 10.1159/000314315

165

Ritzel K., Beuschlein F., Mickisch A., Osswald A. et. al. Outcome of Bilateral Adrenalectomy in et alCushing’s Syndrome: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism 2013; 98(10): 3939– 3948. doi: 10.1210/jc.2013-1470

166

Lenders J.W.M., Duh Q.-Y., Eisenhofer G. et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: 10.1210/jc.2014-1498

167

Lenders J.W.M., Kerstens M.N., Amar L., et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443-1456. doi: 10.1097/HJH.0000000000002438

168

Calissendorff J., Juhlin C.C., Bancos I. et al. Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance. Cancers (Basel). 2022 Feb 12;14(4):917. doi: 10.3390/cancers14040917

169

Falhammar H., Kjellman M., Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7(1):186-192. doi: 10.1530/EC-17-0321

170

Ebbehoj A., Stochholm K., Jacobsen S.F. et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J. Clin. Endocrinol. Metab. 2021;106:e2251– e2261. doi: 10.1210/clinem/dgaa965

171

Mete O., Asa S.L., Gill A.J. et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6

172

Garcia-Carbonero R., Matute Teresa F., Mercader-Cidoncha E. et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021 Oct;23(10):1995-2019. doi: 10.1007/s12094-021-02622-9

173

Fishbein L., Del Rivero J., Else T. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021;50(4):469-493. doi: 10.1097/MPA.0000000000001792

174

Zuber S.M., Kantorovich V., Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311, vii. doi: 10.1016/j.ecl.2011.02.002

175

Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539-553. doi: 10.1210/er.2002-0013

176

Geroula A., Deutschbein T., Langton K. et al. (2019). Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 181(4):409-420. doi: 10.1530/EJE-19-0159

177

Мохорт Т.В., Велесевич Е.И., Мохорт Е.Г.(2016). Феохромоцитома: современные подходы к диагностике и лечению. Медицинские новости. 2016;(4):3-10.

Mokhort T.V., Velesevich E.I., Mokhort E.G. Pheochromocytoma: new approaches to diagnosis and management, Meditsinskie novosti. 2016;(4):3-10 (in Russ.).

178

Calhoun D.A., Jones D., Textor S. et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141

179

Y-Hassan S., Falhammar H. Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas. J Clin Med. 2020 Jul 30;9(8):2435. doi: 10.3390/jcm9082435

180

Бельцевич Д.Г., Трошина Е.А., Юкина М.Ю. Феохромоцитома. Проблемы эндокринологии . 2010; 56 (1), 63-71. doi: 10.14341/probl201056163-71

Bel’tsevich D.G., Troshina E.A., Iukina M.I. Pheochromocytoma. Problems of Endocrinology. 2010;56(1):63-71. (In Russ). doi: 10.14341/probl201056163-71

181

Zelinka T., Pacák K., Widimský J. Jr. Characteristics of blood pressure in pheochromocytoma. Ann N Y Acad Sci. 2006 Aug;1073:86-93. doi: 10.1196/annals.1353.009

182

Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018;62(3):566-575. doi: 10.1007/s12020-018-1734-x

183

Мельниченко Г.А., Трошина Е.А., Бельцевич Д.Г. и соавт. Клинические рекомендации Российской Ассоциации эндокринологов по диагностике и лечению феохромоцитомы/параганглиомы. Эндокринная хирургия. 2015;9(3):15-33. doi: 10.14341/serg2015315-33

Mel’nichenko G.A., Troshina E.A., Bel’tsevich D.G., et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33 (In Russ.). doi: 10.14341/serg2015315-33

184

Antonio K., Valdez M.M.N., Mercado-Asis L., et al. Pheochromocytoma/ paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020 Feb;9(1):105-123. doi: 10.21037/gs.2019.10.25

185

Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г. Наследственные синдромы, ассоциированные с феохромоцитомой. Часть 1. Терапевтический архив. 2015;87(9):102-105. doi: 10.17116/terarkh2015879102-105

Iukina M.Iu., Troshina E.A., Bel’tsevich D.G. Hereditary pheochromocytoma-associated syndromes. Part 1. Terapevticheskii Arkhiv. 2015;87(9):102-105. (In Russ.). doi: 10.17116/terarkh2015879102-105

186

Plouin P.F., Amar L., Dekkers O.M., et al. Guideline Working Group European Society of Endocrinology Clinical Practice Guideline for longterm follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur. J. Endocrinol. 2016;174:G1–G10. doi: 10.1530/EJE16-0033

187

Weismann D., Liu D., Bergen T., et al. Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of phaeochromocytoma. Clin. Endocrinol. 2015;82(2):188–196. doi: 10.1111/cen.12536

188

Bahn R.S., Burch H.B., Cooper D.S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and American association of clinical endocrinologists. Endocr. pract. 2011;17(3):456-520. doi: 10.4158/ep.17.3.456

189

Ross D.S., Burch H.B., Cooper D.S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi: 10.1089/thy.2016.0229

190

Российская ассоциация эндокринологов. Национальные рекомендации: Тиреотоксикоз с диффузным зобом (диффузный токсический зоб, болезнь Грейвса–Базедова), узловым/многоузловым зобом. М.; 2014.

Russian Association of Endocrinologists. National recommendations: Thyrotoxicosis with diffuse goiter (diffuse toxic goiter, Graves–Basedow disease), nodular/multinodular goiter. M.; 2014 (in Russ.).

191

William F. Young Jr., Calhoun D.A. et al. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Reviews. 2017;3(2):103-122. doi: 10.1210/er.2017-00054

192

Selmer C., Olesen J.B., Hansen M.L. et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014;99(7):2372-2382. doi: 10.1210/jc.2013-4184

193

Sohn S.Y., Lee E., Lee M.K. et al. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis and systematic review of cohort studies. Endocrinol Metab (Seoul). 2020;35(4):786-800. doi: 10.3803/EnM.2020.728

194

Berta, E., Lengyel, I., Halmi, S. et al. Hypertension in Thyroid Disorders. Front. Endocrinol. 2019;10:482. doi: 10.3389/fendo.2019.00482

195

Kahaly G.J., Olivo P.D. Graves’ disease. N Engl J Med. 2017;376(2):184. doi: 10.1056/NEJMc1614624

196

Tozzoli R., Bagnasco M., Giavarina D. et al. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi: 10.1016/j.autrev.2012.07.003

197

Kahaly G.J., Bartalena L., Hegedus L. The American Thyroid Association/ American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid. 2011;21(6):585–591. doi: 10.1089/thy.2011.2106.ed3

198

Collet T.H., Gussekloo J., Bauer D.C. et al. Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809. doi: 10.1001/archinternmed.2012.402

199

Bartalena L., Burch H.B., Burman K.D. et al. A 2013 European survey of clinical practice patterns in the management of Graves ‘disease. Clin Endocrinol. 2016;84(1):115–120. doi: 10.1111/cen.12688

200

Чазова И.Е., Голицын С.П., Жернакова Ю.В. и соавт. Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий. Системные гипертензии. 2021;18(3):105–128. doi: 10.26442/2075082X.2021.3.201077

Chazova I.E., Golitsyn S.P., Zhernakova Ju.V. et al. Management of patients with arterial hypertension and atrial fibrillation. Systemic Hypertension. 2021;18(3):105–128 (In Russ.). doi: 10.26442/2075082X.2021.3.201077

201

Corvilain B., Hamy A., Brunaud L. et al. Treatment of adult Graves’ disease. Ann Endocrinol (Paris) (2018). doi: 10.1016/j.ando.2018.08.003

202

Kahaly G.J., Bartalena L., Hegedüs L. et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167–186. doi: 10.1159/000490384

203

Brito J.P., Schilz S., Singh Ospina N. et al. Antithyroid drugs – the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145. doi: 10.1089/thy.2016.0222

204

Biondi B., Bartalena L., Cooper D.S. et al. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. doi: 10.1159/000438750

205

Tagami T., Yambe Y., Tanaka T. et al. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285– 2290. doi: 10.2169/internalmedicine.51.7302

206

Satoh T., Isozaki O., Suzuki A. et al. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63:1025–1064. doi: 10.1507/endocrj.EJ16-0336

207

Isozaki O., Satoh T., Wakino S. et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016;84:912–918. doi: 10.1111/cen.12949

208

Meyerovitch J., Rotman-Pikielny P., Sherf M. et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med. 2007;167(14):1533–8. doi: 10.1001/archinte.167.14.1533.

209

Persani L., Cangiano B., Bonorni M. The diagnosis and management of central hypothyroidism in 2018. Endocr Connect. 2019;8(2):44-54. doi: 10.1530/EC-18-0515

210

Mazza A., Beltramello G., Armigliato M. et al. Arterial hypertension and thyroid disorders: What is important to know in clinical practice? Ann Endocrinol. 2011;72:296–303. doi: 10.1016/j.ando.2011.05.004

211

Piantanida E., Gallo D., Veronesi G. et al. Masked hypertension in newly diagnosed hypothyroidism: a pilot study. J Endocrinol Invest. 2016;39(10):1131-1138. doi: 10.1007/s40618-016-0488-7.

212

Surks M.I., Ortiz E., Daniels G. et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Jama. 2004;291(2):228-238. doi: 10.1001/jama.291.2.228

213

Raber W., Gessl A., Nowotny P. et al. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid. 2002; 12(8):725-731. doi: 10.1089/105072502760258712

214

McAninch E.A., Rajan K.B., Miller C.H. et al. Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(12):4533- 4542. doi: 10.1210/jc.2018-01361

215

Jonklaas J., Bianco A.C., Bauer A.J. et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028

216

Покровский А.В., Зотиков А.Е., Юдин В.И. Неспецифический аортоартериит (болезнь Такаясу). М.: ИРИСЪ, 2002.

Pokrovskij A.V., Zotikov A.E., Yudin V.I. Nonspecific aortoarteritis (Takayasu’s disease). M.: IRIS, 2002 (in Russ.)

217

Arnaud L., Haroche J., Limal N. et al. Takayasu arteritis in France: a singlecenter retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore). 2010;89(1):1-17. doi: 10.1097/MD.0b013e3181cba0a3

218

Saadoun D., Bura-Riviere A., Comarmond C. et al. French recommendations for the management of Takayasu’s arteritis. Orphanet J Rare Dis. 2021 Jul 21;16(Suppl 3):311. doi: 10.1186/s13023-021-01922-1

219

Mammeri A., Guermaz R., Hatri A. et al. L’hypertension artérielle au cours de la maladie de Takayasu: à propos d’une série monocentrique de 279 patients [Hypertension during Takayasu’s disease: An Algerian single center experience of 279 patients]. Ann Cardiol Angeiol (Paris). 2017;66(3):154-158. doi: 10.1016/j.ancard.2017.04.006

220

Чихладзе, Н. М., Сивакова, О. А., Чазова, И. Е. Клинические проявления поражения сердечно-сосудистой системы при неспецифическом аортоартериите. Системные гипертензии. 2008;5(4)22-24. doi: 10.26442/SG28828

Chikhladze, N. M., Sivakova, O. A., Chazova, I. E. Clinical manifestations of damage of cardiovascular system in Takayasu arteritis Systemic Hypertension. 2008;5(4)22-24 (in Russ). doi: 10.26442/SG28828

221

Ham S.W., Kumar S.R., Rowe V.L. et al. Disease progression after initial surgical intervention for Takayasu arteritis. J Vasc Surg. 2011;54(5):1345- 1351. doi: 10.1016/j.jvs.2011.04.044

222

Чихладзе Н.М. Артериальная гипертония у больных неспецифическим аортоартериитом. Системные гипертензии. 2018;15(2):43– 48. doi: 10.26442/2075-082X_2018.2.43-48.

Chikhladze N.M. Arterial hypertension in patients with non-specific aortoarteritis. Systemic Hypertension. 2018;15(2):43-48 (in Russ). doi: 10.26442/2075-082X_2018.2.43-48.

223

Ying S., Sifan W., Yujiao W. et al. Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension. Arthritis Res Ther. 2021;23(1):196. Published 2021 Jul 21. doi: 10.1186/s13075-021-02579-8

224

Арабидзе Г.Г., Абугова С.П., Матвеева Л.С и соавт. Клинические аспекты болезни Такаясу (215 наблюдений). Терапевт. Архив. 1980;5:124– 129.

Arabidze G.G., Abugova S.P., Matveeva L.S. et al. Clinical aspects of Takayasu’s disease (215 cases). Terapevt. Arhiv. 1980;5:124–129 (in Russ).

225

Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000-1009. doi:10.1002/art.22404

226

Erbel R., Aboyans V., Boileau C. et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281

227

Maz M., Chung S.A., Abril A. et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774

228

Águeda A.F., Monti S., Luqmani R.A. et al. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open 2019;5:e001020. doi: 10.1136/rmdopen-2019-001020

229

Сторжаков Г.И. Артериальные гипертонии при пороках сердца и аорты. В кн.: Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. – М.: Медиа Медика, 2005. – С. 1.

Storzhakov G.I. Arterial hypertension in heart and aorta defects. In: Guide to Arterial Hypertension. Ed. E.I. Chazova, I.E. Chazovoi. - M.: Media Medica, 2005. - S. 1 (in Russ).

230

Клинические рекомендации. Коарктация аорты. МЗ РФ, 2020

231

Бураковский В.И. и соавт. Врожденные пороки сердца. В кн.: Сердечно-сосудистая хирургия. Под ред. Бураковского В.И. и Бокерии Л.А. – М.:Медицина. 1996. – C. 299-312.

Burakovsky V.I. et al. Congenital heart disease. In: Cardiovascular Surgery. Ed. Burakovsky V.I., Bokeria L.A. – M.: Medicine. 1996. - p. 299-312 (in Russ).

232

Покровский А.В. Коарктация аорты. В кн.: Заболевания аорты и ее ветвей. – М.: Медицина, 1979. – C. 269-302.

Pokrovsky A.V. Coarctation of the aorta. In: Diseases of the aorta and its branches. - M.: Medicine, 1979. - p. 269-302 (in Russ).

233

Hemels M.E., Hoendermis E.S., van Melle J.P. et al. Therapy refractory hypertension in adults: aortic coarctation has to be ruled out. Neth Heart J. 2011 Mar;19(3):107-111. doi: 10.1007/s12471-011-0074-8

234

Erbel R., Aboyans V., Boileau, C. et al. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC), European Heart Journal, Volume 35, Issue 41, 1 November 2014, Pages 2873–2926. doi: 10.1093/eurheartj/ehu281

235

Stout K.K., Daniels C.J., Aboulhosn J.A. et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e698–e800. doi: 10.1161/CIR.0000000000000603

236

Hiratzka L.F., Bakris G.L., Beckman J.A. et al. 2010 ACCF/AHA/AATS/ ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in Circulation. 2010 Jul 27;122(4):e410]. Circulation. 2010;121(13):e266-e369. doi: 10.1161/CIR.0b013e3181d4739e

237

Ильин А.С., Теплов П.В., Сакович В.А. Коарктация аорты как патология сердечно-сосудистой системы. Наши возможности в хирургии. Сибирское медицинское обозрение. 2018;(3): 24-33. doi: 10.20333/2500136-2018-3-24-33

Ilin A.S., Teplov P.V., Sakovich V.A. Aorta coarctation as a pathology of cardiovascular system. Our potential in surgery. Siberian Medical Review.2018;(3): 24- 33 (in Russ.). doi: 10.20333/2500136-2018-3-24-33

238

Vohra H.A., Adamson L., Haw M.P. Does surgical correction of coarctation of the aorta in adults reduce established hypertension? Interact Cardiovasc Thorac Surg. 2009;8(1):123-127. doi:10.1510/icvts.2008.185736

239

Bhat M.A., Neelakandhan K.S., Unnikrishnan M. et al. Fate of hypertension after repair of coarctation of the aorta in adults. Br J Surg. 2001;88(4):536- 538. doi: 10.1046/j.1365-2168.2001.01745.x

240

Torok R.D., Campbell M.J., Fleming G.A. et al. Coarctation of the aorta: Management from infancy to adulthood. World J Cardiol. 2015;7(11):765- 775. doi: 10.4330/wjc.v7.i11.765

241

Parati G., Lombardi C., Hedner J. et al.; European Respiratory Society; EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012 Apr;30(4):633-46. doi: 10.1097/HJH.0b013e328350e53b

242

Sateia M.J. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-1394. doi: 10.1378/chest.14-0970

243

Young T., Palta M., Dempsey J. et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ. 2009 Aug;108(5):246-9.

244

Benjafield A.V., Ayas N.T., Eastwood P.R. et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7:687–98. doi: 10.1016/S2213-2600(19)30198-5

245

Lindberg E., Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev. 2000 Oct;4(5):411-33. doi: 10.1053/smrv.2000.0118

246

Аксенова А.В., Елфимова Е.М., Галицин П.В. и др. Значение компьютерной пульсоксиметрии в практике врача-кардиолога. Системные гипертензии. 2014;11(4):26-30.

Aksenova A.V., Elfimova E.M., Galitsin P.V. et al. Role of the Pulse Oximetry in the cardiologist’s practice. Systemic Hypertension. 2014;11(4):26–30 (in Russ.).

247

Бочкарев М.В., Коростовцева Л.С., Фильченко И.А. и соавт. Жалобы на нарушения дыхания во сне и факторы риска сердечно-сосудистых заболеваний в регионах России: данные исследования ЭССЕ-РФ. Рос кардиол журн. 2018;6:152–158.

Bochkarev M.V., Korostovtseva L.S., Filchenko I.A. et al. Complaints on sleep breathing disorder and cardiovascular risk factors in Russian regions: data from ESSE-RF study. Russ. J. Cardiol. 2018;6:152–158 (In Russ).

248

Khokhrina A., Andreeva E., Degryse J.M. The prevalence of sleepdisordered breathing in Northwest Russia: The ARKHsleep study. Chron Respir Dis. 2020 Jan-Dec;17:1479973120928103. doi: 10.1177/1479973120928103

249

Nieto F.J., Young T.B., Lind B.K. et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000 Apr 12;283(14):1829- 36. doi: 10.1001/jama.283.14.1829. Erratum in: JAMA 2002 Oct 23- 30;288(16):1985.

250

Peppard P.E., Young T., Palta M. et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378-84. doi: 10.1056/NEJM200005113421901

251

Lavie P., Herer P., Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000 Feb 19;320(7233):479-82. doi: 10.1136/bmj.320.7233.479.

252

Tokunou T., Ando S.I. Recent advances in the management of secondary hypertension-obstructive sleep apnea. Hypertens Res. 2020 Dec;43(12):1338-1343. doi: 10.1038/s41440-020-0494-1

253

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 Aug 1;22(5):667-89.

254

Kapur V.K., Auckley D.H., Chowdhuri S. et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Mar 15;13(3):479-504. doi: 10.5664/jcsm.6506

255

Somers V.K., White D.P., Amin R. et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008 Aug 19;52(8):686-717. doi: 10.1016/j.jacc.2008.05.002

256

Johns M.W. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest. 1993 Jan;103(1):30-6. doi: 10.1378/chest.103.1.30

257

Jordan A.S., McSharry D.G., Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014 Feb 22;383(9918):736-47. doi: 10.1016/S0140-6736(13)60734-5

258

Giles T.L., Lasserson T.J., Smith B.J. et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106. doi: 10.1002/14651858.CD001106. pub2. Update in: Cochrane Database Syst Rev. 2006;(3):CD001106.

259

Walia H.K., Thompson N.R., Pascoe M. et al. Effect of Positive Airway Pressure Therapy on Drowsy Driving in a Large Clinic-Based Obstructive Sleep Apnea Cohort. J Clin Sleep Med. 2019 Nov 15;15(11):1613-1620. doi: 10.5664/jcsm.8024

260

US Preventive Services Task Force. Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(19):1945–1950. doi: 10.1001/jama.2022.20304

261

Liu L., Cao Q., Guo Z. et al. Continuous positive airway pressure in patients with obstructive sleep apnea and resistant hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2016 Feb;18(2):153-8. doi: 10.1111/jch.12639

262

Montesi S.B., Edwards B.A., Malhotra A. et al. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med. 2012 Oct 15;8(5):587-96. doi: 10.5664/jcsm.2170

263

Litvin A.Y., Sukmarova Z.N., Elfimova E.M. et al. Effects of CPAP on «vascular» risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-235. doi: 10.2147/VHRM.S40231

264

Patil S.P., Ayappa I.A., Caples S.M. et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019 Feb 15;15(2):335-343. doi: 10.5664/jcsm.7640

265

Epstein L.J., Kristo D., Strollo P.J Jr., et al. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 Jun 15;5(3):263-76.

266

Grossman A., Messerli F.H., Grossman E. Drug induced hypertension--An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015 Sep 15;763(Pt A):15-22. doi: 10.1016/j.ejphar.2015.06.027

267

Lovell A.R., Ernst M.E. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017 May;19(5):39. doi: 10.1007/s11906-017-0736-z. PMID: 28451850.

268

Aronow W.S. Drug-induced causes of secondary hypertension. Ann Transl Med. 2017 Sep;5(17):349. doi: 10.21037/atm.2017.06.16

The authors declare that there are no conflicts of interest present.